<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Xeris Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc</link>
<description>Latest news and press releases for Xeris Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/xeris-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835daca78dffbe2df12399d.webp</url>
<title>Xeris Pharmaceuticals Inc</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc</link>
</image>
<item>
<title>Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-to-report-first-quarter-2026-financial-results-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-to-report-first-quarter-2026-financial-results-on-may-7-2026</guid>
<pubDate>Thu, 23 Apr 2026 11:30:00 GMT</pubDate>
<description>CHICAGO, April 23, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2026 financial results before the open of the U.S. financial markets on Thursday, May 7, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company</description>
</item>
<item>
<title>Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-reports-record-performance-for-fourth-quarter-and-full-year-2025-and-provides-full-year-2026-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-reports-record-performance-for-fourth-quarter-and-full-year-2025-and-provides-full-year-2026-guidance</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of</description>
</item>
<item>
<title>Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-subsidiaries-file-recorlevr-patent-infringement-lawsuit</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-subsidiaries-file-recorlevr-patent-infringement-lawsuit</guid>
<pubDate>Thu, 26 Feb 2026 22:55:00 GMT</pubDate>
<description>CHICAGO, February 26, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that its subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, have filed a patent infringement lawsuit under the Hatch-Waxman Act related to Recorlev® (levoketoconazole) in the United States District Court for the District of New Je</description>
</item>
<item>
<title>Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-report-full-2025-123000394</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-report-full-2025-123000394</guid>
<pubDate>Tue, 17 Feb 2026 12:30:00 GMT</pubDate>
<description>CHICAGO, February 17, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results before the open of the U.S. financial markets on Monday, March 2, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to d</description>
</item>
<item>
<title>Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-expects-deliver-record-fourth-quarter-and-full-year-2025-total-revenue-2026-01</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-expects-deliver-record-fourth-quarter-and-full-year-2025-total-revenue-2026-01</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>Anticipates full year 2025 total revenue of $292 million, exceeding the guidance range of $285-$290 million and reflecting growth of 44% compared to the</description>
</item>
<item>
<title>Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Fri, 02 Jan 2026 05:00:00 GMT</pubDate>
<description>CHICAGO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology</description>
</item>
<item>
<title>Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-announces-notice-allowance-us-patent-and-trademark-office-xp-8121-patent</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-announces-notice-allowance-us-patent-and-trademark-office-xp-8121-patent</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by</description>
</item>
<item>
<title>Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-posts-record-financial-results-third-quarter-2025-2025-11-06</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-posts-record-financial-results-third-quarter-2025-2025-11-06</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Total product revenue increased 40% YoY to $74 million Recorlev® revenue grew 109% YoY to $37 million Updating full-year 2025 total revenue guidance to</description>
</item>
<item>
<title>Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-report-third-quarter-2025-financial-results-november-6-2025-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-report-third-quarter-2025-financial-results-november-6-2025-2025-10</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>Conference Call to be Held at 8:30 a.m. ET CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company</description>
</item>
<item>
<title>Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-1</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-1</guid>
<pubDate>Fri, 03 Oct 2025 04:00:00 GMT</pubDate>
<description>CHICAGO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology</description>
</item>
<item>
<title>Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-announces-orange-book-listing-us-patent-recorlevr-2025-08-25</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-announces-orange-book-listing-us-patent-recorlevr-2025-08-25</guid>
<pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
<description>Recorlev now holds four Orange Book-listed patents to 2040 CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing</description>
</item>
<item>
<title>Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-reports-record-financial-results-second-quarter-2025-and-raises-full</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-reports-record-financial-results-second-quarter-2025-and-raises-full</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>Total revenue increased 49% YoY to $71.5 million; Recorlev® revenue grew 136% YoY Raises full-year 2025 total revenue guidance to $280-$290 million from</description>
</item>
<item>
<title>Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-report-second-quarter-2025-financial-results-august-7-2025-2025-07-31</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-report-second-quarter-2025-financial-results-august-7-2025-2025-07-31</guid>
<pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by</description>
</item>
<item>
<title>Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-unveils-strategy-long-term-growth-and-value-creation-2025-analyst-investor-day</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-unveils-strategy-long-term-growth-and-value-creation-2025-analyst-investor-day</guid>
<pubDate>Tue, 03 Jun 2025 04:00:00 GMT</pubDate>
<description>Company to discuss long-range financial outlook and strategic roadmap for rapid and sustainable growth CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings,</description>
</item>
<item>
<title>Xeris Announces Details for Analyst & Investor Day</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-announces-details-analyst-investor-day-2025-05-20</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-announces-details-analyst-investor-day-2025-05-20</guid>
<pubDate>Tue, 20 May 2025 04:00:00 GMT</pubDate>
<description>Hybrid Event Offering In-Person or Virtual Attendance on Tuesday, June 3, 2025 CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a</description>
</item>
<item>
<title>Xeris Biopharma Reports Record First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-reports-record-first-110000481</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-reports-record-first-110000481</guid>
<pubDate>Thu, 08 May 2025 11:00:00 GMT</pubDate>
<description>CHICAGO, May 08, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance.</description>
</item>
<item>
<title>Xeris Biopharma Reports Record First Quarter 2025 Financial Results </title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-reports-record-first-quarter-2025-financial-results-2025-05-08</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-reports-record-first-quarter-2025-financial-results-2025-05-08</guid>
<pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
<description>Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million</description>
</item>
<item>
<title>Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-report-first-quarter-2025-financial-results-may-8-2025-2025-05-01</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-biopharma-report-first-quarter-2025-financial-results-may-8-2025-2025-05-01</guid>
<pubDate>Thu, 01 May 2025 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by</description>
</item>
<item>
<title>Xeris Announces Changes to Its Board of Directors</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-announces-changes-its-board-directors-2025-03-28</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-announces-changes-its-board-directors-2025-03-28</guid>
<pubDate>Fri, 28 Mar 2025 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by</description>
</item>
<item>
<title>Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid</title>
<link>https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-announces-approval-supplemental-new-drug-application-snda-gvoke-vialdxtm</link>
<guid isPermaLink="true">https://6ix.com/company/xeris-pharmaceuticals-inc/news/xeris-announces-approval-supplemental-new-drug-application-snda-gvoke-vialdxtm</guid>
<pubDate>Mon, 17 Mar 2025 04:00:00 GMT</pubDate>
<description>First concentrated, ready-to-dilute liquid glucagon available for growing procedural gastroenterology market American Regent to commercialize GVOKE VialDx™</description>
</item>
</channel>
</rss>